deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT01897532

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk

Sponsor: Boehringer Ingelheim

Conditions Diabetes Mellitus, Type 2
Interventions Linagliptin Placebo
Updated 18 times since 2017 Last updated: Mar 21, 2019 Started: Jul 10, 2013 Primary completion: Jan 18, 2018 Completion: Jan 18, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01897532, this PHASE4 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 18 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Apr 2017 · 3 months · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Dec 2017 · 4 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Feb 2019 · 5 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Jan 2021 · 20 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

18 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE4

  2. Nov 2025 — Dec 2025 [monthly]

    Completed PHASE4

  3. Oct 2025 — Nov 2025 [monthly]

    Completed PHASE4

  4. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE4

  5. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

▶ Show 13 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  2. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  3. May 2019 — Jan 2021 [monthly]

    Completed PHASE4

  4. Feb 2019 — May 2019 [monthly]

    Completed PHASE4

  5. Sep 2018 — Feb 2019 [monthly]

    Completed PHASE4

  6. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE4

  7. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  8. Feb 2018 — Mar 2018 [monthly]

    Active Not Recruiting PHASE4

  9. Dec 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE4

  10. Aug 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE4

  11. Jun 2017 — Aug 2017 [monthly]

    Active Not Recruiting PHASE4

  12. Apr 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE4

  13. Jan 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE4

    First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
  • Eli Lilly and Company
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adrogué, Argentina , Afula, Israel , Aichi, Nagoya, Japan , Airdrie, United Kingdom , Akron, United States , Alba Iulia, Romania , Alberton, South Africa , Albuquerque, United States , Almería, Spain , Alor Star, Malaysia and 430 more locations